A proposed securities class action against ARS Pharmaceuticals Inc. gives investors until October 5, 2026 to seek appointment as lead plaintiff. The case covers purchasers of the company's securities between March 9, 2026 and June 24, 2026. The lawsuit alleges ARS misled investors about when expanded CVS Caremark insurance coverage for its epinephrine nasal spray, neffy, would begin, including statements that coverage would start on July 1, 2026 and be in place for the summer and back-to-school allergy seasons. The complaint claims those statements inflated the stock price and that investors were harmed when the fuller details reached the market.